Compare Ares Capital Corporation (ARCC) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs ARK Genomic Revolution ETF — how do they compare? Ares Capital Corporation trades at $19.79 (market cap $14.34B), while ARK Genomic Revolution ETF trades at $44.47. The key difference: Ares Capital Corporation pays a 9.61% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Ares Capital Corporation nearer its low. Which is the better fit depends on your goals.
| ARCC | ARKG | |
|---|---|---|
Market Cap | $14.34B | — |
Sector | Financials | Sector/Thematic |
52-Week High | $22.68 | $44.55 |
52-Week Low | $17.45 | $24.02 |
Dividend Yield | 9.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARCC trades at $19.98, down 0.15% on the day, with a P/E of 14.9 and P/B of 1.03. Recent quarterly earnings have consistently missed expectations, with Q2 2026 EPS of $0.47 falling short of the $0.4731 estimate. Technical indicators show a bullish moving average signal but bearish oscillators, with RSI at 78.37 suggesting overbought conditions. The company maintains a strong dividend yield of approximately 9.6% with consistent $0.48 quarterly payments.
While ARCC offers attractive income with its high dividend yield and strong analyst support (24 buy ratings), investors face risks from declining revenue trends and compressed earnings. The stock trades near consensus price targets, limiting near-term upside potential. Credit quality concerns in the private lending sector and potential interest rate sensitivity present additional headwinds for this business development company.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
